Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 9/12/2025

Methyl Folate for ADHD: Efficacy and Contraindications

Genetic Considerations

  • Variants in genes encoding glutathione S transferase (GST), monoamine oxidase (MAOA), and methionine synthase (MS) have been associated with reduced attentiveness and response speed in some ADHD populations, according to the Annual Review of Medicine 1, 2
  • Genetic variations affecting folate metabolism, including MTHFR polymorphisms, may influence the effectiveness of folate supplementation, with some individuals potentially benefiting more than others based on their genetic profile, as reported in Stroke 3

First-Line Treatments for ADHD

  • Stimulant medications (methylphenidate and amphetamines) remain the first-line pharmacological treatment for ADHD due to their superior efficacy, rapid onset of action, and extensive evidence base, as stated by Praxis Medical Insights 4
  • For children and adolescents with ADHD, FDA-approved medications along with behavioral interventions are recommended as standard treatment, according to Pediatrics 5
  • Non-stimulant medications such as atomoxetine, extended-release guanfacine, and extended-release clonidine are considered second-line options when stimulants are ineffective or poorly tolerated, as noted by Praxis Medical Insights 4

Potential Contraindications and Precautions with Methyl Folate

  • Individuals with certain genetic polymorphisms affecting folate metabolism may experience different responses to methyl folate supplementation, as reported in Stroke 3
  • Methyl folate may interact with certain medications, including those affecting folate metabolism or requiring folate as a cofactor, according to Stroke 3